The invention provides an anti-CEA antibody for use in detecting CEA, treating disorders associated with CEA expression, diagnosing cancers characterized by aberrant CEA expression, and predicting effectiveness of cancer drug therapies.

The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also disclosers immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.

The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

Disclosed are a monoclonal antibody and antigen-binding fragment thereof which can specifically bind to human carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5); also disclosed is a chimeric antigen receptor based on said antibody, and a method for preparing said antibody and antigen-binding fragment and use thereof for treating CEACAM5-related tumors.

Provided herein is technology for screening multiple types of cancer from a biological sample, and particularly, but not exclusively, to methods, compositions, and related uses for simultaneously detecting the presence of multiple types of cancer (e.g., liver cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, gastric cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, prostate cancer, renal cancer, and uterine cancer) from a biological sample (e.g., stool sample, tissue sample, organ secretion sample, CSF sample, saliva sample, blood sample, plasma sample or urine sample).

It is an object of the present invention to provide a fusion protein of an antibody that recognizes cancer cells and a mutant streptavidin, which is for use in the treatment or diagnosis of cancer. According to the present invention, provided is a fusion protein having the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 7, a linker sequence, and the amino acid sequence as set forth in SEQ ID NO: 1 (provided that the amino acid sequence portion consisting of 6 histidine residues at the C-terminus thereof may be partially or entirely deleted), from the N-terminal side to the C-terminal side, in this order.

The present invention provides methods of detecting increased carcinoembryonic antigen-related cell adhesion molecule (CEACAM) protein expression in a biological sample from a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene. The invention also provides methods of treating or preventing inflammatory bowel disease (IBD) in a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene.

A method for preparing a nanohybrid used for ratiometric fluorescence and ratiometric electrochemical sensing simultaneously is provided. Surface-aminated (—NH.sub.2) SiO.sub.2 nanospheres encapsulating an electroactive material A or B are prepared and conjugated with surface-carboxylated (—COOH) carbon dots (CDs) or gold nanoclusters (AuNCs) to prepare a conjugate, and the conjugate is conjugated with a DNA aptamer terminated with —NH.sub.2. Ions or biomolecules are added to two types of DNA-conjugate dispersions, and ratiometric florescence sensing is realized by fitting the linear relationship between ratiometric fluorescent peak intensity IcDs/IAuNcs and a specific ion concentration or a specific biomolecule concentration. A-SiO.sub.2@CDs-DNA is attached to the surface of a gold electrode based on a DNA terminal —SH and Au-S bonding; B-SiP.sub.2@AuNCs-DNA and ions or biomolecules are added, and ratiometric electrochemical sensing is realized by fitting the linear relationship between the specific ion concentration or the specific biomolecule concentration and the ratiometric current peak intensity IB/IA

A method for preparing a nanohybrid used for ratiometric fluorescence and ratiometric electrochemical sensing simultaneously is provided. Surface-aminated (—NH.sub.2) SiO.sub.2 nanospheres encapsulating an electroactive material A or B are prepared and conjugated with surface-carboxylated (—COOH) carbon dots (CDs) or gold nanoclusters (AuNCs) to prepare a conjugate, and the conjugate is conjugated with a DNA aptamer terminated with —NH.sub.2. Ions or biomolecules are added to two types of DNA-conjugate dispersions, and ratiometric florescence sensing is realized by fitting the linear relationship between ratiometric fluorescent peak intensity I.sub.CDs/I.sub.AuNCs and a specific ion concentration or a specific biomolecule concentration. A-SiO.sub.2@CDs-DNA is attached to the surface of a gold electrode based on a DNA terminal —SH and Au—S bonding; B—SiO.sub.2@AuNCs-DNA and ions or biomolecules are added, and ratiometric electrochemical sensing is realized by fitting the linear relationship between the specific ion concentration or the specific biomolecule concentration and the ratiometric current peak intensity I.sub.B/I.sub.A.